Eric Rutaganda

Eric Rutaganda

Auto-generated profile, based on publicly available information

Eric Rutaganda

Department of Pathology, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in International Journal of Mathematics and Mathematical Sciences
Verified
Journal Article
Open access
PDF file
WBWellars Banzi
Wellars Banzi
IKImmaculate Kambutse
Immaculate Kambutse
VDVincent Dusabejambo
Vincent Dusabejambo
EREric Rutaganda
Eric Rutaganda
FMFroduald Minani
Froduald Minani
JNJean Marie Ntaganda
Jean Marie Ntaganda
This paper presents a mathematical model of glucose‐insulin dynamics which is specific for type 2 diabetic patients. The general modelling is obtained by simplification of a global compartmental model by John Thomas Sorensen. The model parameters are estimated using nonlinear optimization and data collected in Rwanda for type 2 diabetic patients. In order to identify and evaluate possible abnormalities of type 2 diabetic patients, the Sampling Importance Resampling (SIR) particle filtering algorithm is used and implemented through discretization of the developed mathematical model. This process is done by clamping insulin and glucose concentrations at around clinical trial values as proposed by Defronzo. Furthermore, for detecting potential abnormalities in type 2 diabetic patients, we compare our results with results obtained from a simulation of the mathematical model for healthy subjects. The proposed mathematical model allows further investigation of the dynamic behavior of glucose, insulin, glucagon, stored insulin, and labile insulin in different organs for type 2 diabetic patients.

Verified
Journal Article
Open access
PDF file
FMFelix MANIRAKIZA
Felix MANIRAKIZA
EREric Rutaganda
Eric Rutaganda
HYHidetaka YAMADA
Hidetaka YAMADA
YIYuji Iwashita
Yuji Iwashita
BRBelson Rugwizangoga
Belson Rugwizangoga
Haruhiko SugimuraHaruhiko Sugimura
Haruhiko Sugimura
Cancer research in Rwanda is estimated to be less than 1% of the total African cancer research output with limited research on colorectal cancer (CRC). Rwandan patients with CRC are young, with more females being affected than males, and most patients present with advanced disease. Considering the paucity of oncological genetic studies in this population, we investigated the mutational status of CRC tissues, focusing on the Adenomatous polyposis coli (APC), Kirsten rat sarcoma (KRAS), and Homeobox B13 (HOXB13) genes. Our aim was to determine whether there were any differences between Rwandan patients and other populations. To do so, we performed Sanger sequencing of the DNA extracted from formalin-fixed paraffin-embedded adenocarcinoma samples from 54 patients (mean age: 60 years). Most tumors were located in the rectum (83.3%), and 92.6% of the tumors were low-grade. Most patients (70.4%) reported never smoking, and 61.1% of patients had consumed alcohol. We identified 27 variants of APC, including 3 novel mutations (c.4310_4319delAAACACCTCC, c.4463_4470delinsA, and c.4506_4507delT). All three novel mutations are classified as deleterious by MutationTaster2021. We found four synonymous variants (c.330C>A, c.366C>T, c.513T>C, and c.735G>A) of HOXB13. For KRAS, we found six variants (Asp173, Gly13Asp, Gly12Ala, Gly12Asp, Gly12Val, and Gln61His), the last four of which are pathogenic. In conclusion, here we contribute new genetic variation data and provide clinicopathological information pertinent to CRC in Rwanda.

8 March 2024 in Genes and Environment
Verified
Journal Article
Open access
PDF file
ANAugustin Nzitakera
Augustin Nzitakera
JSJean Bosco Surwumwe
Jean Bosco Surwumwe
Ndoricyimpaye Ella LarissaNdoricyimpaye Ella Larissa
Ndoricyimpaye Ella Larissa
SUSchifra Uwamungu
Schifra Uwamungu
DUDelphine Uwamariya
Delphine Uwamariya
Kazuya ShinmuraKazuya Shinmura
Kazuya Shinmura
Background: Gastric cancer is the sixth most frequently diagnosed cancer and third in causing cancer-related death globally. The most frequently mutated gene in human cancers is TP53, which plays a pivotal role in cancer initiation and progression. In Africa, particularly in Rwanda, data on TP53 mutations are lacking. Therefore, this study intended to obtain TP53 mutation status in Rwandan patients with gastric cancer. Results: Formalin-fixed paraffin-embedded tissue blocks of 95 Rwandan patients with histopathologically proven gastric carcinoma were obtained from the University Teaching Hospital of Kigali. After DNA extraction, all coding regions of the TP53 gene and the exon–intron boundary region of TP53 were sequenced using the Sanger sequencing. Mutated TP53 were observed in 24 (25.3%) of the 95 cases, and a total of 29 mutations were identified. These TP53 mutations were distributed between exon 4 and 8 and most of them were missense mutations (19/29; 65.5%). Immunohistochemical analysis for TP53 revealed that most of the TP53 missense mutations were associated with TP53 protein accumulation. Among the 29 mutations, one was novel (c.459_477delCGGCACCCGCGTCCGCGCC). This 19-bp deletion mutation in exon 5 caused the production of truncated TP53 protein (p.G154Wfs*10). Regarding the spectrum of TP53 mutations, G:C > A:T at CpG sites was the most prevalent (10/29; 34.5%) and G:C > T:A was the second most prevalent (7/29; 24.1%). Interestingly, when the mutation spectrum of TP53 was compared to three previous TP53 mutational studies on non-Rwandan patients with gastric cancer, G:C > T:A mutations were significantly more frequent in this study than in our previous study (p = 0.013), the TCGA database (p = 0.017), and a previous study on patients from Hong Kong (p = 0.006). Even after correcting for false discovery, statistical significance was observed. Conclusions: Our results suggested that TP53 G:C > T:A transversion mutation in Rwandan patients with gastric cancer is more frequent than in non-Rwandan patients with gastric cancer, indicating at an alternative etiological and carcinogenic progression of gastric cancer in Rwanda.

1 August 2015 in Clinical Therapeutics
Verified
Journal Article
Open access
ERE. Rutaganda
E. Rutaganda
VDV. Dusabejambo
V. Dusabejambo
JNJ. Nyirigira
J. Nyirigira
DSD.R.J. Singer
D.R.J. Singer

1 January 2026 in ACG Case Reports Journal
Verified
Journal Article
Open access
MMMarie Solange Mukanumviye
Marie Solange Mukanumviye
FGFerehiwot Bekele Getaneh
Ferehiwot Bekele Getaneh
SNSamuel Ndagijimana
Samuel Ndagijimana
ANAntoine Nduwayezu
Antoine Nduwayezu
VDVincent Dusabejambo
Vincent Dusabejambo
KDKulwinder S. Dua
Kulwinder S. Dua
Pancreatic tuberculosis is a rare disease. It mimics both benign and malignant conditions of the pancreas. We describe the case of a man who presented with repetitive epigastric pain and elevated pancreatic enzymes, leading to a presumptive diagnosis of alcohol-induced pancreatitis. Imaging revealed pancreatic pseudocyst, omental thickening, multiple loculated ascites, and bilateral pleural effusions. Despite supportive management for pancreatitis, the patient's symptoms worsened. Further evaluation raised the suspicion of tuberculosis. He was started on antituberculosis therapy. There was complete resolution of his symptoms, pseudocyst and ascites on follow-up imaging. Early suspicion and management of pancreatic tuberculosis may lead to excellent outcomes.

26 June 2026 in BMJ Open Gastroenterology
Verified
Journal Article
Open access
HAHanna Aberra
Hanna Aberra
KDKulwinder S Dua
Kulwinder S Dua
DLDirk J Van Leeuwen
Dirk J Van Leeuwen
FMFlorence Masaisa
Florence Masaisa
GSGamal Salah
Gamal Salah
BRBerhane Redae
Berhane Redae